Figure 1




Figure 2



Nondiabetic range
Log ED50 = -1.246 ? 0.071
ED50 ~ 57 ?g kg-1 day-1
Diabetic range
Velocity (m s-1)
65
60
55
50
-2
-1
0
Dose [log (mg kg-1 day-1)]

Figure 3




Figure 4




Figure 5




Figure 6



Motor conduction velocity
Velocity (m s -1)
66
64
62
60
58
56
54
52
50
-1.5
-1.0
-0.5
0.0
0.5
1.0
Dose [log (mg kg -1 day-1)]
ED50 ~ 0.35 mg/kg
Sensory Conduction Velocity
Velocity (m s -1)
62.5
60.0
57.5
55.0
52.5
50.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
Dose [log (mg kg -1 day-1)]
ED50 ~ 0.27 mg/kg

Figure 7




Figure 8




Figure 9




Figure 10




Figure 11



Corpus cavernosum:
area under the pressure-response curve
to cavernous nerve stimulation
AUC (% systemic pressure . s)
4000
3000
2000
1000
0
1
2
4
8
16
32
Frequency (Hz)

Figure 12




Figure 13




66
64
62
60
58
56
54
52
50
Velocity (m/s)
-3
-2
-1
0
1
2
3
4
log dose (mg/kg)
GLA
13-HODE
15-HETrE

Figure 14


Mean 15-HETrE plasma levels (uL)
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Placebo
13-HODE
15-HETrE